News | November 16, 2024
Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
These accolades highlight our unwavering commitment to maintaining the highest safety standards
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
The leading hospital chain appoints Lokesh Taridalu Shivakumar as Facility Director for Yeshwanthapur hospital
Subscribe To Our Newsletter & Stay Updated
